期刊
CLINICAL CANCER RESEARCH
卷 16, 期 19, 页码 4702-4710出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-10-0939
关键词
-
类别
资金
- Glaxo Smith Klein
- Boehringer-Ingelheim
- Genentech
- Wyeth
- Bristol Myers Squibb
- BiPAR/Sanofi Aventis
- NCI [CA058223]
- NIH [R01 CA108794]
- Breast Cancer Research Foundation
- Susan G. Komen for the Cure
- National Cancer Institute at the Dana-Farber/Harvard Cancer Center [CA089393]
- Cogan Family Foundation
- Canadian Breast Cancer Research Foundation
- [5K12CA120780-03]
- NATIONAL CANCER INSTITUTE [P50CA089393, P50CA058223, R01CA108794, K12CA120780] Funding Source: NIH RePORTER
In contrast to endocrine-sensitive and human epidermal growth factor receptor 2 (HER2)-positive breast cancer, novel agents capable of treating advanced triple-negative breast cancer (TNBC) are lacking. Poly (ADP-ribose) polymerase (PARP) inhibitors are emerging as one of the most promising targeted therapeutics to treat TNBC, with the intended target being DNA repair. PARPs are a family of enzymes involved in multiple cellular processes, including DNA repair. TNBC shares multiple clinico-pathologic features with BRCA-mutated breast cancers, which harbor dysfunctional DNA repair mechanisms. Investigators hypothesized that PARP inhibition, in conjunction with the loss of DNA repair via BRCA-dependent mechanisms, would result in synthetic lethality and augmented cell death. This hypothesis has borne out in both preclinical models and in clinical trials testing PARP inhibitors in both BRCA-deficient and triple-negative breast cancer. The focus of this review includes an overview of the preclinical rationale for evaluating PARP inhibitors in TNBC, the presumed mechanism of action of this novel therapeutic class, promising results from several influential clinical trials of PARP inhibition in advanced breast cancer (both TNBC and BRCA deficient), proposed mechanisms of acquired resistance to PARP inhibitors, and, finally, concludes with current challenges and future directions for the development of PARP inhibitors in the treatment of breast cancer. Clin Cancer Res; 16(19); 4702-10. (C) 2010 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据